Clin2
NCT07518121Likely a fitNot yet recruiting

Safety study of efsubaglutide in healthy Brazilian adults

Diabete Type 2

Treatments studied

Part of Hormones & metabolism clinical trials.

This is an early-stage safety study testing a new medication called efsubaglutide in healthy adults. Researchers want to make sure it is safe and understand how the body processes it.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
48 people
Ages
18 years to 45 years
Study type
Interventional

Who can take part

  • You are between 18 and 45 years old
  • Your BMI (weight-to-height ratio) is between 18 and 28, and you weigh at least 50 kg (men) or 45 kg (women)
  • You are in good overall health with no diabetes, prediabetes, or thyroid problems
  • You have not donated blood or had major surgery in the past 3 months
  • You do not use recreational drugs and limit alcohol to 14 drinks per week or less
  • You are willing to use effective birth control for 3 months after the study ends (if applicable)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06900075Not yet recruiting· Phase 3
Efsubaglutide injection every 2 weeks for Type 2 diabetes

This trial tests a new injectable medicine (efsubaglutide alfa) given once every two weeks to help control blood sugar in people with Type 2 diabetes who have not taken diabetes medications for at least 8 weeks. It aims to see if it is safe and works better than a placebo.

NCT07693426Recruiting· Phase 1
Study of efsubaglutide alfa for obese teenagers

This trial tests an injection called efsubaglutide alfa to help obese teenagers lose weight. It requires following diet and exercise advice for at least 3 months before starting.

Beijing, Beijing Municipality
NCT07114419Recruiting· Phase 2
New weekly injection for weight loss in overweight or obesity

This study tests a new weekly injection, efsubaglutide alfa (a GLP-1 drug), for helping people with overweight or obesity lose weight. It is for people who have not been able to lose weight with diet and exercise alone and do not have other serious health conditions.

Brookvale
NCT07415954Recruiting· Phase 2
Testing a new diabetes medicine for blood sugar control

This study tests a new medicine, NNC0662-0419, in people with type 2 diabetes. You must be willing to lose a lot of weight (more than a quarter of your current weight) as part of the study to see if the medicine helps lower blood sugar.

Lancaster, California
NCT07156539Not yet recruiting· Phase 3
Study of an investigational diabetes drug

This trial tests an investigational medication (HS-20094) for people with type 2 diabetes. It aims to see if it can help control blood sugar and possibly support weight loss.

Jinan, Shandong
NCT07424430Not yet recruiting
Long-term study of semaglutide effects on heart, kidney, and metabolic health

This study looks at how semaglutide (a medication for type 2 diabetes or weight management) affects your heart, kidneys, and overall metabolic health over time. It uses medical records from LMC endocrinology clinics to track real-world outcomes.

Hear when a new Diabete Type 2 trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.